The three schedules people ask about are not equivalent, and the difference between them is not preference. One of them gives away the entire reason to pair these two compounds.
No approval, no trial
None of the schedules below has been studied for this combination. What follows reasons from the single-agent pharmacology — the co-administration synergy, the circadian GH pattern, and the insulin effect — to what each schedule can and cannot deliver. It is not a recommendation to run any of them.
Study-supported reasoning
Both together, at night — the strongest case
Pathophysiology
The largest natural GH release of the day occurs in roughly the first two hours of sleep, tied to slow-wave sleep. Administration inside that window produces higher peak GH than daytime dosing.
Mechanistic rationale
This schedule is the only one that collects both available advantages. You get the co-administration synergy — two to three times the GH response of either agent alone — and you get it on top of the natural nocturnal pulse rather than against a flat baseline. It is also the convention tesamorelin is conventionally dosed on, though note the label itself does not specify a time.
Community reports
The most commonly run schedule, and the one most associated with the improved-sleep reports. The recurring complaint is grogginess when the dose is taken too close to sleep.
Components carrying the argument: Both compounds, one injection window, fasted 2 h before bed
Theorized
Both together, in the morning — keeps the synergy, loses the tailwind
Pathophysiology
Morning dosing fires into a period with no natural pulse to amplify and, typically, higher somatostatin tone. The synergy between the two compounds is unaffected, because that depends on co-administration rather than on time of day.
Mechanistic rationale
The practical case is real and is usually undersold: a genuine fast is trivially easy on waking and difficult before bed, and since insulin blunts the pituitary response, a properly fasted morning dose may beat a poorly fasted evening one. It also removes any sleep interference. What it gives up is the circadian amplification — the same dose produces a lower peak outside the sleep window. Note the limit of the counter-evidence: work showing comparable outcomes from morning versus evening dosing was done with exogenous GH replacement, which is not the same thing as amplifying an endogenous pulse.
Community reports
Less common. Chosen most often by people who eat late, who found evening dosing disrupted sleep, or who dislike hunger from ipamorelin at bedtime.
Components carrying the argument: Both compounds, one injection window, fasted on waking
Theorized — and it forfeits the mechanism
Split — ipamorelin at night, tesamorelin in the morning
Pathophysiology
The supra-additive response depends on both receptors being engaged at once: the GHRH arm driving release while the ghrelin arm suppresses somatostatin. Separated by twelve hours, neither is present when the other acts.
Mechanistic rationale
This is the schedule to understand before choosing it, because it gives away the entire reason to pair these two compounds. Run apart, you get two independent single-agent pulses instead of one combined pulse two to three times larger. You are not splitting the effect in half; you are trading a documented synergy for two smaller separate events. The honest counter-argument: two pulses a day arguably resembles physiological secretion more closely than one large one, and pulsatility is a principle this library takes seriously elsewhere. But that is a theorised benefit set against a measured one, and if the pulsatility argument is what appeals, running both compounds together twice a day achieves it without giving up the synergy.
Community reports
Reported, usually justified on convenience — ipamorelin at night for sleep, tesamorelin in the morning to avoid stacking injections. The convenience is real; the pharmacological cost is rarely mentioned alongside it.
Components carrying the argument: Compounds separated by ~12 h — no co-administration
Mechanistic
What applies to all three
Pathophysiology
Insulin suppresses the pituitary response to a secretagogue regardless of the hour chosen.
Mechanistic rationale
Fasted state matters more than the clock. A dose given after a carbohydrate meal is a smaller dose in effect, whichever schedule it belongs to. The other constant is consistency: the guidance around tesamorelin timing is that regularity matters more than the specific hour, and switching schedules week to week gives up whatever advantage any of them has.
Community reports
Fasting is the protocol rule most often skipped and most likely to explain a non-response.
Components carrying the argument: Applies to every schedule above
What actually has evidence for these conditions
The measurable thing is IGF-1, and it settles this argument better than reasoning does. Every schedule above is an inference from single-agent pharmacology, because the combination has never been studied. IGF-1 is the marker the approved half is monitored on, it is orderable through any GP or private lab, and it responds to total GH exposure across the day rather than to how the dose was arranged. Anyone genuinely trying to decide between these schedules has a way to find out which one works for them, and it costs less than a vial.
Worth stating plainly alongside that: for the outcomes people usually want from this pairing, the interventions with function data are sleep, progressive resistance training and adequate protein. The GH axis is an adjunct to those, and the ROMANA result — lean mass up, function unchanged — is the reason this library keeps saying so.
